Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphenyl Phosphate SCHEMBL5550628 | 1.00 | SRC (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL18116 | 0.97 | SRC (0.64) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL28761613 | 0.97 | SRC (0.64) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL28557783 | 0.97 | SRC (0.64) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL483692 | 0.97 | SRC (0.64) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL1924512 | 0.94 | SRC (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| SCHEMBL10015245 | 0.94 | CYP3A4 (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL15815456 | 0.94 | SRC (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| SCHEMBL131239 | 0.94 | CYP3A4 (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 | |
| Triphenyl Phosphate SCHEMBL2530073 | 0.94 | SRC (0.61) | SRCL3MBTL1TDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122999-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230110705-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4122999-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-01-25 | — | — | EP | disclosed |
| US-10098896-B2 | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| EP-2206719-B1 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-17-(1-H-BENZIMIDAZOLE-1-YL)ANDROSTA-5,16-DIENE | UNIV MARYLAND (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140288036-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-09-25 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2206719-A2 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor | University Of Maryland (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-06-03 | — | — | US | disclosed |
| EP-1853619-A4 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIV MARYLAND (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-11-13 | — | — | US | disclosed |
| EP-1853619-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | University of Maryland (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006093993-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-0703791-B1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RES BIOCHEMICALS LTD PATERNERS (US) | 2002-12-04 | — | — | EP | disclosed |
| US-5698179-A | Iodinated neuroprobe for mapping monoamine reuptake sites | NEURO IMAGING TECHNOLOGIES, LLC (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0703791-A4 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RES BIOMED LP (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0703791-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOMEDICALS LIMITED PARTNERSHIP (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5439666-A | Central nervous system | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1995001184-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098896-B2 | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity | CYP17A1, HSD17B1, HSD17B7 | SRC 1064/4885L3MBTL1 3039/4885TDP1 2874/4885 |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP17A1, HSD17B1, HSD17B7 | SRC 1095/4885L3MBTL1 3339/4885TDP1 2897/4885 |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, CYP21A2, HSD17B1 | SRC 1934/4885L3MBTL1 3666/4885TDP1 1879/4885 |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, CYP21A2 | SRC 1068/4885L3MBTL1 3399/4885TDP1 2825/4885 |
| US-20140288036-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP17A1, HSD17B1, HSD17B7 | SRC 1095/4885L3MBTL1 3339/4885TDP1 2897/4885 |
| US-20230110705-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | L1CAM, NOM1, LEF1 | SRC 3354/4885L3MBTL1 19/4885TDP1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.